RSS-Feed abonnieren
DOI: 10.1055/s-0043-1777360
Optimizing the Outcome of Pediatric Metastatic Neuroblastoma in a Nontransplant Setting in a Developing Country: Retrospective Study from a Tertiary Cancer Center in India
Funding None declared.
Abstract
Objective This article estimates the survival of children over 1 year of age diagnosed with metastatic neuroblastoma (NB) and treated in a nontransplant facility and determines the factors affecting survival.
Materials and Method Case records of children aged 1 to 14 years treated for metastatic NB in our center from January 2008 to December 2017 were studied. Patients received conventional chemotherapy followed by surgery, radiotherapy, and metronomic maintenance chemotherapy.
Results Eighty-nine patients with metastatic NB received treatment. Mean age was 3.5 years and male:female ratio was 1.1:1. The most common primary site was suprarenal (55%) and the most common site of metastasis was bone marrow (76%). Forty percent patients had multiple metastatic sites. Mean baseline lactate dehydrogenase (LDH) was 3724 U/L (range 303–16609 U/L) and 65% patients had LDH > 750 U/L. Fifty-three patients (59.6%) had good response to chemotherapy as evidenced by clearance of metastatic disease, but out of them, 43 patients (81%) progressed subsequently. Twenty-six patients underwent surgery and 12 patients received maintenance therapy. Seventy-four patients (86%) developed recurrence and all but one died. Median time to recurrence and death were 9 months (range 0–120 months) and 10 months (range 1–123 months), respectively. At a median follow-up of 72 months (range 15–135 months), 16 patients are alive, with 5-year disease-free survival and overall survival of 17.6 and 18.4%, respectively. Age, baseline LDH, chemotherapy regimen, and response to treatment significantly affected survival.
Conclusion Younger age, lower baseline LDH, and good response to chemotherapy appear to confer survival advantage in pediatric metastatic NB, and may be used for optimization of treatment in the nontransplant setting in developing countries.
Patient Consent
Consent for treatment and use of medical record data for scientific studies were routinely obtained for all patients.
Publikationsverlauf
Artikel online veröffentlicht:
26. August 2024
© 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)
Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
-
References
- 1 Kusumakumary P, Ajithkumar TV, Ratheesan K, Chellam VG, Nair MK. Pattern and outcome of neuroblastoma. A 10 year study. Indian Pediatr 1998; 35 (03) 223-229
- 2 Parikh NS, Howard SC, Chantada G. et al; International Society of Pediatric Oncology. SIOP-PODC adapted risk stratification and treatment guidelines: recommendations for neuroblastoma in low- and middle-income settings. Pediatr Blood Cancer 2015; 62 (08) 1305-1316
- 3 Bansal D, Marwaha RK, Trehan A, Rao KL, Gupta V. Profile and outcome of neuroblastoma with convertional chemotherapy in children older than one year: a 15-years experience. Indian Pediatr 2008; 45 (02) 135-139
- 4 Jain R, Trehan A, Menon P. et al. Survival in patients with high-risk neuroblastoma treated without autologous stem cell transplant or dinutuximab beta. Pediatr Hematol Oncol 2021; 38 (04) 291-304
- 5 Lucena JN, Alves MTS, Abib SCV, Souza GO, Neves RPC, Caran EMM. Clinical and epidemiological characteristics and survival outcomes of children with neuroblastoma: 21 years of experience at the Instituto de Oncologica Pediatrica, in São Paulo, Brazil. Rev Paul Pediatr 2018; 36 (03) 254-260
- 6 Aksoylar S, Varan A, Vergin C. et al. Treatment of high-risk neuroblastoma: national protocol results of the Turkish Pediatric Oncology Group. J Cancer Res Ther 2017; 13 (02) 284-290
- 7 Morgenstern DA, London WB, Stephens D. et al. Prognostic significance of pattern and burden of metastatic disease in patients with stage 4 neuroblastoma: a study from the International Neuroblastoma Risk Group database. Eur J Cancer 2016; 65: 1-10
- 8 Schmidt ML, Lal A, Seeger RC. et al. Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: a Children's Cancer Group Study. J Clin Oncol 2005; 23 (27) 6474-6480
- 9 Moroz V, Machin D, Hero B. et al. The prognostic strength of serum LDH and serum ferritin in children with neuroblastoma: a report from the International Neuroblastoma Risk Group (INRG) project. Pediatr Blood Cancer 2020; 67 (08) e28359
- 10 Cheung NV, Heller G. Chemotherapy dose intensity correlates strongly with response, median survival, and median progression-free survival in metastatic neuroblastoma. J Clin Oncol 1991; 9 (06) 1050-1058
- 11 Kusumakumari P, Ajithkumar TV, Hariharan S. et al. Intensive chemotherapy in children with stage IV neuroblastoma. Indian J Pediatr 1999; 66 (06) 867-872